Your browser is no longer supported. Please, upgrade your browser.
Settings
MRNS Marinus Pharmaceuticals, Inc. daily Stock Chart
MRNS [NASD]
Marinus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.47 Insider Own0.10% Shs Outstand21.38M Perf Week0.98%
Market Cap33.03M Forward P/E- EPS next Y-1.10 Insider Trans-97.23% Shs Float19.53M Perf Month11.96%
Income-28.60M PEG- EPS next Q-0.30 Inst Own38.10% Short Float12.87% Perf Quarter70.00%
Sales- P/S- EPS this Y11.80% Inst Trans-24.17% Short Ratio1.50 Perf Half Y-28.80%
Book/sh1.10 P/B1.40 EPS next Y-4.80% ROA-67.80% Target Price3.50 Perf Year-70.40%
Cash/sh1.41 P/C1.10 EPS next 5Y- ROE-94.60% 52W Range0.82 - 6.76 Perf YTD52.97%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-77.14% Beta-
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin- 52W Low88.12% ATR0.10
Employees14 Current Ratio3.70 Sales Q/Q- Oper. Margin- RSI (14)58.05 Volatility5.58% 7.27%
OptionableNo Debt/Eq0.24 EPS Q/Q30.80% Profit Margin- Rel Volume0.20 Prev Close1.54
ShortableYes LT Debt/Eq0.08 EarningsMar 20 AMC Payout- Avg Volume1.68M Price1.54
Recom2.00 SMA203.07% SMA5013.04% SMA20010.63% Volume342,463 Change0.32%
Aug-10-16Reiterated Jefferies Buy $2.50 → $3
Jun-14-16Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-08-16Reiterated Stifel Buy $23 → $16
Dec-17-15Initiated RBC Capital Mkts Outperform $14
Nov-17-15Initiated Jefferies Buy $14
Oct-30-15Reiterated Oppenheimer Outperform $21 → $17
Aug-05-15Reiterated Oppenheimer Outperform $12 → $21
Mar-23-17 08:43AM  Ultragenyxs Seizure Drug Fails Study at Investopedia
Mar-22-17 04:16PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a +5.52%
Mar-16-17 01:04PM  MARINUS PHARMACEUTICALS INC Financials
Mar-15-17 07:30AM  Marinus Pharmaceuticals to Present at Oppenheimer Healthcare Conference GlobeNewswire
Mar-13-17 07:35AM  MARINUS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report +8.97%
07:30AM  Marinus Pharmaceuticals Provides Business Update and 2016 Financial Results GlobeNewswire
Feb-14-17 07:30AM  Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model GlobeNewswire
Feb-01-17 04:07PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
07:30AM  Marinus Appoints Michael R. Dougherty to its Board of Directors GlobeNewswire
Jan-24-17 08:20AM  Marinus Releases Positive Preliminary Data from CDKL5 Study
07:20AM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jan-23-17 03:42PM  Why This Seizure Drug Matters So Much for Marinus Pharma +18.10%
11:20AM  Marinus Anti-Seizure Drug Did Well in Early Trial at Investopedia
10:57AM  Marinus Pharma stock surges 49% on positive mid-stage data for pediatric epilepsy drug at MarketWatch
07:30AM  Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder GlobeNewswire
Jan-19-17 05:16PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jan-09-17 06:09AM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits +11.89%
Jan-05-17 07:30AM  Marinus Provides Business Outlook for 2017 GlobeNewswire
Jan-03-17 10:40AM  Main Line biopharm firm gets a boost from the FDA at bizjournals.com
07:30AM  Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome GlobeNewswire
Nov-21-16 04:04PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
Nov-17-16 12:21PM  5 Stocks Under $10 Poised for Big Breakouts
Nov-15-16 07:30AM  Ganaxolone and Diazepam Administered Intravenously Synergistically Block Seizures in Animal Model of Status Epilepticus GlobeNewswire
Nov-08-16 04:40PM  MARINUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Nov-03-16 08:02AM  Marinus Pharmaceuticals posts 3Q loss -7.08%
07:30AM  Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2016 Financial Results GlobeNewswire
Oct-24-16 06:04AM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Oct-19-16 09:54AM  Heres Why Investors Are Watching Sangamo Biosciences, GNC Holdings, and Three Other Stocks Today at Insider Monkey +5.76%
07:30AM  Ganaxolone Phase 1 Data Supports Progressing to Phase 2 in Patients with Status Epilepticus GlobeNewswire
Oct-11-16 11:44AM  Marinus Pharmaceuticals, Inc. to Present at The MicroCap Conference on October 24-25 in Philadelphia Accesswire
Oct-03-16 06:09AM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Sep-29-16 09:00AM  Ganaxolone Reduces Seizures in Females with PCDH19 Pediatric Epilepsy GlobeNewswire -26.74%
Sep-23-16 01:45PM  Why These 5 Stocks Are Winning Today at Insider Monkey +26.14%
Sep-07-16 04:06PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure,
07:30AM  Marinus Appoints Seth H.Z. Fischer to its Board of Directors GlobeNewswire
Aug-09-16 07:47PM  Marinus Pharmaceuticals posts 2Q loss
04:35PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:17PM  MARINUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
04:15PM  Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2016 Financial Results GlobeNewswire
Jul-13-16 12:08PM  Cheap Stocks: These Aren't Necessarily a Lucky 7 +13.55%
07:17AM  7 Stocks Under $10 That Could Make You a Lot of Money
Jun-28-16 10:37AM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:30AM  Results from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome GlobeNewswire
Jun-27-16 04:05PM  Marinus Pharmaceuticals to Host Conference Call on Tuesday, June 28 GlobeNewswire -7.46%
Jun-22-16 07:30AM  Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV GlobeNewswire
Jun-19-16 10:15AM  6 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
Jun-14-16 09:46AM  Marinus Stock Down on Dismal Phase III Data on Ganaxolone -11.73%
06:05AM  Marinus Pharmaceuticals downgraded by RBC Capital Mkts
Jun-13-16 01:40PM  5 Stocks That Have Kicked Off the Week on a Sour Note at Insider Monkey -69.66%
12:39PM  Radnor biopharm's stock plunges following disappointing seizure treatment study at bizjournals.com
10:51AM  Stocks Seesaw as 'Brexit' Fears, Fed Feed Nerves
09:50AM  Why Marinus Pharmaceuticals Shares Are Sliding at 24/7 Wall St.
08:47AM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:47AM  Stock Futures Slide; Microsoft to Buy LinkedIn
08:04AM  Marinus Pharma's trial of treatment for drug-resistant epilepsy failed to meet goals at MarketWatch
07:48AM  Marinus' drug for focal onset seizures fails in late-stage study
07:30AM  Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures GlobeNewswire
Jun-08-16 06:02PM  Marinus Pharmaceuticals, Inc. :MRNS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016
May-03-16 07:30AM  Marinus Pharmaceuticals to Participate in Bank of America Merrill Lynch Healthcare Conference GlobeNewswire +9.23%
May-02-16 05:34PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
05:26PM  MARINUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
07:40AM  Marinus Pharmaceuticals posts 1Q loss
07:30AM  Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2016 Financial Results GlobeNewswire
Apr-21-16 04:54PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Apr-19-16 07:30AM  Marinus Pharmaceuticals Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus GlobeNewswire
Apr-17-16 07:49AM  8 Stocks Under $10 to Trade for Big Gains at TheStreet
Apr-15-16 07:30AM  Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus GlobeNewswire +8.70%
Apr-12-16 07:30AM  Marinus Pharmaceuticals to Present Ganaxolone IV Data at American Academy of Neurology Annual Meeting GlobeNewswire +6.75%
Mar-24-16 10:50AM  These 5 Under-$10 Stocks Are Set to Soar Higher at TheStreet +6.10%
Mar-07-16 05:23PM  MARINUS PHARMACEUTICALS INC Files SEC form 10-K, Annual Report +23.44%
07:47AM  Marinus Pharmaceuticals posts 4Q loss
07:30AM  Marinus Pharmaceuticals Provides Business Update and 2015 Financial Results GlobeNewswire
Mar-01-16 12:59PM  The Stock Picks of This Obscure Hedge Fund Returned 70.5% In 2015; See What Its Betting On in 2016 at Insider Monkey
07:30AM  Marinus Pharmaceuticals to Present at the Cowen & Company Annual Healthcare Conference GlobeNewswire
Feb-26-16 10:19AM  Marinus Pharmaceuticals (MRNS) Enters Oversold Territory
Jan-27-16 07:34AM  Marinus Pharmaceuticals to Participate in Canaccord Genuity Rare Disease Biopharma Day at noodls
07:30AM  Marinus Pharmaceuticals to Participate in Canaccord Genuity Rare Disease Biopharma Day GlobeNewswire
Jan-04-16 05:12PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and -5.63%
Dec-18-15 07:35AM  How it All Plays Out - Free Research Reports on Hill International, Marinus Pharmaceuticals, Ampio Pharmaceuticals and Cutera Accesswire +12.52%
06:44AM  4 Biotech Stocks Under $10 Poised for Big Breakouts at TheStreet
Dec-16-15 07:30AM  Marinus Pharmaceuticals Completes Patient Recruitment in Phase 3 Clinical Trial of Ganaxolone in Focal Onset Seizures GlobeNewswire
Dec-07-15 09:10AM  Marinus Presents Additional Responder Analysis Data for Ganaxolone in Focal Onset Seizures at the American Epilepsy Society Annual Meeting GlobeNewswire
Dec-03-15 07:30AM  Marinus Pharmaceuticals Bolsters Clinical and Regulatory Expertise GlobeNewswire -7.86%
Nov-27-15 08:32AM  Marinus Pharmaceuticals Inc (MRNS): Are Hedge Funds Right About This Stock? at Insider Monkey
Nov-23-15 08:40AM  Origins of Technical Movement, Pricing Tomorrow - Research on Zynerba Pharmaceuticals, Emergent Capital, Marinus Pharmaceuticals, and Comstock Resources Accesswire
Nov-19-15 07:30AM  Marinus's Ganaxolone to be Featured in Two Poster Presentations at the 69th Annual Meeting of the American Epilepsy Society GlobeNewswire
Nov-12-15 07:30AM  Marinus Pharmaceuticals to Present at Stifel Healthcare Conference GlobeNewswire
Nov-10-15 07:30AM  Marinus Pharmaceuticals to Present At Credit Suisse Healthcare Conference GlobeNewswire
Nov-06-15 04:35PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S -26.91%
09:08AM  Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
Nov-05-15 04:01PM  Marinus Pharmaceuticals Announces Public Offering of Common Stock GlobeNewswire
Oct-29-15 04:45PM  MARINUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report -8.97%
04:44PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
08:03AM  Marinus Pharmaceuticals posts 3Q loss
07:45AM  Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2015 Financial Results GlobeNewswire
07:30AM  Marinus Announces Clinical Development Plans for Ganaxolone Intravenous Formulation GlobeNewswire
Oct-26-15 07:30AM  Marinus Announces Key Initial Observations From Study in PCDH19 Female Pediatric Epilepsy GlobeNewswire
Sep-10-15 04:45PM  Marinus' End-of-Phase II Meeting Positive for Ganaxolone
Sep-09-15 07:30AM  Marinus Pharmaceuticals Announces Positive End-of-Phase 2 Meeting With FDA for Ganaxolone in Focal Onset Seizures GlobeNewswire
Aug-13-15 05:14PM  MARINUS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement -6.26%
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. It is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of orphan disease, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing an IV formulation for use in the hospital setting to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mehra Anand10% OwnerOct 20Sale1.39750,6831,042,69915,470Oct 24 04:49 PM
Canaan VII LP10% OwnerAug 08Sale1.5019,95029,9251,850,783Aug 09 10:03 AM
Canaan VII LP10% OwnerAug 05Sale1.50129,204193,8061,870,733Aug 09 10:03 AM
Canaan VII LP10% OwnerAug 04Sale1.503,3294,9941,999,937Aug 05 10:18 AM
Canaan VII LP10% OwnerAug 03Sale1.50142,254213,3812,003,266Aug 05 10:18 AM
Canaan VII LP10% OwnerJul 29Sale1.7124,54041,9632,145,520Aug 02 12:22 PM
Canaan VII LP10% OwnerJul 27Sale1.802093762,170,060Jul 27 04:30 PM
Canaan VII LP10% OwnerJul 26Sale1.8120,38036,8882,170,269Jul 27 04:30 PM
Canaan VII LP10% OwnerJul 25Sale1.86137,617255,9682,190,649Jul 26 10:08 AM
Canaan VII LP10% OwnerJul 22Sale1.94133,133258,2782,328,266Jul 26 10:08 AM